#United States #Boulder #Cardiovascular #Edgewise Therapeutics #EWTX

Edgewise Therapeutics Expands Workforce with New Inducement Grants

Edgewise Therapeutics, Inc., a prominent player in the biopharmaceutical sector, is paving its way toward addressing serious cardiovascular diseases through a strategic expansion of its workforce. On August 31, 2026, the company announced the granting of inducement stock options and restricted stock units to a select group of four new non-executive employees. This decision aligns with the company's commitment to lease top-tier talent as it endeavors to develop innovative solutions for patients suffering from cardiovascular issues.

The inducement grants consist of stock options allowing the purchase of up to 21,000 shares of common stock and RSUs covering 10,501 shares, under the provisions of the company's 2024 Inducement Equity Incentive Plan. Each option and RSU award is designed to vest under specific conditions, ensuring that both the company and its employees work towards shared success and sustainable growth.

The stock options issued have an exercise price of $41.77, which reflects the closing market price on the date of the grants. The vesting schedule for the options is attractive: 25% will vest on the first anniversary of the employees' respective start dates, with the remaining 75% vesting monthly thereafter—contingent upon their continued service with Edgewise.

Simultaneously, the RSU awards will gradually vest over a four-year period, reinforcing the long-term commitment expected from the employees. One-fourth of the RSUs will vest at each yearly anniversary of the grant date, implementing a structure that supports retention and encourages a deep-rooted connection to the company’s mission.

This inducement program was executed in compliance with Nasdaq Listing Rule 5635(c)(4), aimed at further bolstering Edgewise’s potential to attract and retain exceptional talent in the competitive biopharmaceutical landscape.

About Edgewise Therapeutics

Edgewise Therapeutics stands at the forefront of the biopharmaceutical industry, focusing on groundbreaking therapeutics aimed at serious cardiovascular and cardiometabolic diseases. With a robust background in integrated muscle physiology and small molecule drug development, the company's mission is to address significant unmet clinical needs, particularly in areas like hypertrophic cardiomyopathy and heart failure.

As it advances its pipeline of cardiovascular therapies, Edgewise is steadily enhancing its collaborative environment, ensuring that its employees are deeply connected to the impactful work that the organization is undertaking.

For further details about Edgewise Therapeutics and its ongoing endeavors, feel free to visit edgewisetx.com or follow the company on social media platforms, including LinkedIn, X, Facebook, and Instagram.

Through these developments, Edgewise Therapeutics not only reinforces its leadership in the biopharmaceutical space but also reaffirms its dedication to tackling the most pressing health challenges within cardiovascular care.